Tarsus Pharmaceuticals Inc (NASDAQ: TARS) kicked off on Friday, down -6.83% from the previous trading day, before settling in for the closing price of $23.43. Over the past 52 weeks, TARS has traded in a range of $12.57-$42.50.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -17.43% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 20.30%. With a float of $31.03 million, this company’s outstanding shares have now reached $34.21 million.
In an organization with 244 employees, it is important to assess its efficiency.
Tarsus Pharmaceuticals Inc (TARS) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Tarsus Pharmaceuticals Inc is 17.86%, while institutional ownership is 98.73%. The most recent insider transaction that took place on Jun 18 ’24, was worth 286,924. In this transaction an insider of this company sold 10,445 shares at a rate of $27.47, taking the stock ownership to the 18,136 shares. Before that another transaction happened on Mar 18 ’24, when Company’s President/CEO and Board Chair sold 10,415 for $30.60, making the entire transaction worth $318,699. This insider now owns 26,456 shares in total.
Tarsus Pharmaceuticals Inc (TARS) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 20.30% per share during the next fiscal year.
Tarsus Pharmaceuticals Inc (NASDAQ: TARS) Trading Performance Indicators
Take a look at Tarsus Pharmaceuticals Inc’s (TARS) current performance indicators. Last quarter, stock had a quick ratio of 7.92. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 19.38.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.77, a number that is poised to hit -0.92 in the next quarter and is forecasted to reach -1.82 in one year’s time.
Technical Analysis of Tarsus Pharmaceuticals Inc (TARS)
Let’s dig in a bit further. During the last 5-days, its volume was 0.7 million. That was inferior than the volume of 0.7 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 6.82%. Additionally, its Average True Range was 1.80.
During the past 100 days, Tarsus Pharmaceuticals Inc’s (TARS) raw stochastic average was set at 1.57%, which indicates a significant decrease from 4.28% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 59.59% in the past 14 days, which was higher than the 57.48% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $29.14, while its 200-day Moving Average is $27.17. However, in the short run, Tarsus Pharmaceuticals Inc’s stock first resistance to watch stands at $22.58. Second resistance stands at $23.34. The third major resistance level sits at $23.88. If the price goes on to break the first support level at $21.29, it is likely to go to the next support level at $20.75. The third support level lies at $19.99 if the price breaches the second support level.
Tarsus Pharmaceuticals Inc (NASDAQ: TARS) Key Stats
The company with the Market Capitalisation of 824.74 million has total of 37,782K Shares Outstanding. Its annual sales at the moment are 17,450 K in contrast with the sum of -135,890 K annual income. Company’s last quarter sales were recorded 27,610 K and last quarter income was -35,730 K.
